Surveillance of Vaccine Safety: Comparison of parental reports with routine surveillance and a clinical trial

Vaccine

Volumn 27, Issue 14, 2009, Pages 2042-2047

  Netterlid, Eva ^a,b   Månsson, Marie Edwinson ^c   Håkansson, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Local reactions; Parental reports; Vaccine safety

Indexed keywords

DIPHTHERIA TETANUS TOXOID; DUPLEX; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CONTROLLED STUDY; CONVULSION; DIPHTHERIA; DISEASE SEVERITY; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; GANGLION CYST; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH PROGRAM; HEALTH SURVEY; HEMATOMA; HUMAN; IMMUNIZATION; INFECTION; INJECTION SITE REACTION; INTERVIEW; LYMPHADENITIS; MAJOR CLINICAL STUDY; NAUSEA; PAIN; PARENT; PARESTHESIA; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SWELLING; TETANUS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

CHILD; CLINICAL TRIALS AS TOPIC; DIPHTHERIA-TETANUS VACCINE; EDEMA; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS; INTERVIEWS AS TOPIC; QUESTIONNAIRES; SAFETY; SENTINEL SURVEILLANCE; SWEDEN;

EID: 61549086525     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.131     Document Type: Article

References (35)

1. Buttery J., La Vincente S., Andrews R., Kempe A., and Royle J. Adverse events following immunisation: desperately seeking surveillance. Lancet Infect Dis 6 (2006) 680-681
2. Wright J.A., and Polack C. Understanding variation in measles-mumps-rubella immunization coverage-a population-based study. Eur J Public Health 16 2 (2006) 137-142
3. Collet J.P., MacDonald N., Cashman N., Pless R., and The Advisory Committee on Causality Assessment. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Bull World Health Organ 78 2 (2000) 178-185
4. Scholtz M., and Duclos P. Immunization safety: a global priority. Bull World Health Organ 78 2 (2000) 153-154
5. Metha U., Milstien J.B., Duclos P., and Folb P.I. Developing a national system for dealing with adverse events following immunization. Bull World Health Organ 78 2 (2000) 170-177
6. Ward B.J. Vaccine adverse events in the new millennium: is there reason for concern?. Bull World Health Organ 78 2 (2000) 205-215
7. Läkemedelsverket [Medical Products Agency]. [Monitoring adverse drug reactions] [Internet]. Uppsala (Sweden). [updated 2007 May 16; cited 2007 July 12]. Available from: http://www.lakemedelsverket.se/Tpl/NormalPage_127.aspx. Swedish.
8. Lankinen K., Pastila S., Kilpi T., Nohynek H., Mäkelä H., and Olin P. Vaccinovigilance in Europe-need for timeliness, standardization and resources. Bull World Health Organ 82 11 (2004) 828-835
9. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12 6 (1994) 542-550
10. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR 52 1 (2003) 1-24
11. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 99 June (6) (1997) 765-773
12. Medicines and Healthcare Products Regulatory Agency (MHRA) Reporting suspected adverse drug reactions and suspected defects in medicinal products. http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Medicines/index.htm. Accessed 2009 January 20.
13. Rothstein E., Kohl K.S., Ball L., Halperin S.A., Halsey N., Hammer S.J., et al. Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 575-585
14. Kohl K.S., Walop W., Gidudu J., Ball L., Halperin S., Hammer S.J., et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 25 August (31) (2007) 5858-5874
15. Gidudu J., Kohl K.S., Halperin S., Hammer S.J., Heath P.T., Hennig R., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 26 December (52) (2008) 6800-6813
16. Halperin S.A., Smith B., Russell M., Scheifele D., Mills E., Hasselback P., et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 19 April (4) (2000) 276-283
17. Rennels M.B., Deloria M.A., Pichichero M.E., Losonsky G.A., Englund J.A., Meade B.D., et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105 January (1) (2000) e12
18. Pichichero M.E., Edwards K.M., Anderson E.L., Rennels M.B., Englund J.A., Yerg D.E., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 105 January (1) (2000) e11
19. Olin P, Rasmusson F, Hallander HO, Heijbel H, for the Ad Hoc Group for the Study of Pertussis Vaccines: Randomised controlled trial of two-component, three-component, and five-component acellular vaccines compared with whole-cell pertussis vaccine. Lancet 1997;350November (9091):1569-77.
20. Olin P, Carlsson RM, Johansen K, Hallander H, Ljungman M, Svensson Å, et al. Vaccinationsuppföljning Seroepidemiologisk tvärsnittsstudie. Final report. 1997. Stockholm (Sweden). Smittskyddinstitutets rapportserie 3:2004. Swedish.
21. Gustafsson L, Hallander HO, Netterlid E, Reizenstein E, Olin P. Antibody responses and clinical reactions to booster doses of TdcP+IPV, TdcP-IPV or DT+IPV at 51/2 years of age after primary immunisation with DTcP (DTPa5) at 3, 5 and 12 months of age in Pertussis Vaccine Trial II. Technical Report. 2000 Sept 9. Available from the Swedish Institute for Infectious Disease Control official register.
22. Communicable Diseases in Sweden 2001: The annual report of the Department of Epidemiology [PDF]. Stockholm: Smittskyddsinsitutet. Available from: http://www.smittskyddsinstitutet.se/upload/Publikationer/Report2001.pdf.
23. Rosenthal S., and Chen R.T. The reporting sensitivities of two passive surveillance system for vaccine adverse events. Am J Public Health 85 12 (1995) 1706-1709
24. Aggerbeck H., Wantzin J., and Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations--III. Vaccine 14 September (13) (1996) 1265-1272
25. Mark A., Carlsson R.-M., and Granström M. Subcutaneus versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 17 (1999) 2067-2072
26. Mark A., and Granström M. The role of aluminium for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine. Acta Pædiatr 83 February (2) (1994) 159-163
27. Blennow M., Granström M., and Strandell A. Adverse reaction after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination. Vaccine 12 5 (1994) 427-430
28. Cassell J.A., Leach M., Poltorak M.S., Mercer C.H., Iversen A., and Fairhead J.R. Is the cultural context of MMR rejection a key to an effective health discourse?. Public Health 120 (2006) 783-794
29. Heininger U. An internet-based survey on parental attitudes towards immunization. Vaccine 24 (2006) 6351-6355
30. Dannetun E., Tegnell A., Hermansson G., and Giesecke J. Parents' reported reasons for avoiding MMR vaccination. Scand J Prim Health Care 23 (2005) 149-153
31. Poland G.A., and Jacobson R.M. Vaccine safety: injecting a dose of common sense. Mayo Clin Proc 75 (2000) 135-139
32. Streefland P., Chowdhury A.M.R., and Ramos-Jimenez P. Patterns of vaccine acceptance. Soc Sci Med 49 (1999) 1705-1716
33. Balinska M. Risky business of vaccine safety. Lancet (Infect Dis Suppl) 1 April (0) (2001) 6
34. Diggle L., and Deeks J. Effect on needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ 321 October (7266) (2000) 931-933
35. EUSAFEVAC. Final Report 2004-03-01, Available at http://www.smittskyddsinstitutet.se/amnesomraden/vaccinationer/eusafevac/eusafevac-documents/ Accessed 2009 January 20.